# Bevacizumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

> **NCT00022659** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 64 (actual)

## Conditions studied

- Primary Peritoneal Cavity Cancer
- Recurrent Ovarian Epithelial Cancer
- Stage IV Ovarian Epithelial Cancer

## Interventions

- **BIOLOGICAL:** bevacizumab
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00022659
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-04
- **Primary completion:** 2010-03
- **Final completion:** 2010-03
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2019-07-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00022659

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00022659, "Bevacizumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00022659. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*